organization · Reporting owner
Marshman Fund Trust II
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | 10% owner | November 01, 2024 | November 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date November 01, 2024 · Filed November 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,051,120 |
Ending reported balance
After 2024-11-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-11-01 · Sale · Disposed 4,000,000 · Balance 6,651,120 Row 2 · 2024-11-05 · Sale · Disposed 600,000 · Balance 6,051,120 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 05, 2024 Filed Nov 5, 2024 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 600,000 | $30.30 | $18,181,500.00 |
DisclosureSEC source: 0001213900-24-094563 · ownership.xml · nonDerivative · entry 2 Marshman Fund Trust II · CIK 0001821461 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,051,120 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,000,000 | $30.30 | $121,210,000.00 |
DisclosureSEC source: 0001213900-24-094563 · ownership.xml · nonDerivative · entry 1 Marshman Fund Trust II · CIK 0001821461 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,651,120 Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 23:43 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionSeries A Preferred Stock · Derivative | 25,983,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023396 · doc4.xml · derivative · entry 2 Marshman Fund Trust II · CIK 0001821461 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,026,784 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F2 · shares: Includes 983,571 shares received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. F1 · derivative.exercise_date: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F2 · derivative.underlying_shares: Includes 983,571 shares received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 23:43 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionCommon Stock | 4,026,784 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-023396 · doc4.xml · nonDerivative · entry 1 Marshman Fund Trust II · CIK 0001821461 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,958,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. Read SEC document |
| August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionSeries A Preferred Stock · Derivative | 25,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024372 · doc4a.xml · derivative · entry 2 Marshman Fund Trust II · CIK 0001821461 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,379,881.68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F2 · derivative.underlying_shares: Includes 336,668.05 shares of common stock received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. Read SEC document |
| August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionCommon Stock | 3,379,881 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-024372 · doc4a.xml · nonDerivative · entry 1 Marshman Fund Trust II · CIK 0001821461 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,379,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. Read SEC document |
| August 21, 2020 Filed Oct 16, 2020 21:00 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | PurchaseCommon Stock | 339,476 | $24.00 | $8,147,424.00 |
DisclosureSEC source: 0000899243-20-028512 · doc4.xml · nonDerivative · entry 1 Marshman Fund Trust II · CIK 0001821461 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,651,120 F1 · balance_after: On September 4, 2020, the reporting person filed a Form 4 amendment that incorrectly stated the number of shares of common stock beneficially owned after the reported transaction. Following the transactions reported hereing, as of August 21, 2020, the reporting person owned 10,651,120 shares of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.